Modifying immune responses to adeno-associated virus vectors by capsid engineering

Abstract excerpt

De novo immune responses are considered major challenges in gene therapy. With the aim to lower innate immune responses directly in cells targeted by adeno-associated virus (AAV) vectors, we equipped the vector capsid with a peptide known to interfere with Toll-like receptor signaling. Specifically, we genetically inserted in each of the 60 AAV2 capsid subunits the myeloid differentiation primary response 88...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to RNA Interference and Gene Delivery
• Share to Viral Infections and Immunology Research
• Share to Virus-based gene therapy research